{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:36:30Z","timestamp":1792726590221,"version":"4.5.0"},"reference-count":143,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Clinical and epidemiological evidence indicate a relationship between thyroid diseases and melanoma. In particular, the hypothyroidism condition appears to promote melanoma spread, which suggests a protective role of thyroid hormones against disease progression. In addition, experimental data suggest that, in addition to thyroid hormones, other hormonal players of the hypothalamic\u2013pituitary\u2013thyroid (HPT) axis, namely the thyrotropin releasing hormone and the thyrotropin, are likely to affect melanoma cells behavior. This information warrants further clinical and experimental studies in order to build a precise pattern of action of the HPT hormones on melanoma cells. An improved knowledge of the involved molecular mechanism(s) could lead to a better and possibly personalized clinical management of these patients.<\/jats:p>","DOI":"10.3390\/ijms231710036","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T05:17:23Z","timestamp":1662441443000},"page":"10036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Is Melanoma Progression Affected by Thyroid Diseases?"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-0759","authenticated-orcid":false,"given":"Salvatore","family":"Ulisse","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-1386","authenticated-orcid":false,"given":"Enke","family":"Baldini","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1545-0779","authenticated-orcid":false,"given":"Daniele","family":"Pironi","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8860-8090","authenticated-orcid":false,"given":"Federica","family":"Gagliardi","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4190-8168","authenticated-orcid":false,"given":"Domenico","family":"Tripodi","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lauro","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Carbotta","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Tarroni","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"D\u2019Armiento","sequence":"additional","affiliation":[{"name":"Scientific Direction, IRCCS San Gallicano Dermatological Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Morrone","sequence":"additional","affiliation":[{"name":"Scientific Direction, IRCCS San Gallicano Dermatological Institute, 00144 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Forte","sequence":"additional","affiliation":[{"name":"Urology Department, M.G. Vannini Hospital, 00177 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flaminia","family":"Frattaroli","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severino","family":"Persechino","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health and Sensory Organs, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Odorisio","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell\u2019Immacolata, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-2530","authenticated-orcid":false,"given":"Vito","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-4952","authenticated-orcid":false,"given":"Eleonora","family":"Lori","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-6648","authenticated-orcid":false,"given":"Salvatore","family":"Sorrenti","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Prinzi, N., Sorrenti, S., Baldini, E., DE Vito, C., Tuccilli, C., Catania, A., Coccaro, C., Bianchini, M., Nesca, A., and Grani, G. (2015). Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122958"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10549-014-2893-y","article-title":"Prevalence of breast cancer in thyroid diseases: Results of a cross-sectional study of 3,921 patients","volume":"144","author":"Prinzi","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10549-012-2019-3","article-title":"Benign thyroid disease is associated with breast cancer: A meta-analysis","volume":"133","author":"Hardefeldt","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/thy.2012.0568","article-title":"Cancer Risk in Patients with Graves\u2019 Disease: A Nationwide Cohort Study","volume":"23","author":"Chen","year":"2013","journal-title":"Thyroid"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/bjc.2013.597","article-title":"Cancer risk in patients with Hashimoto\u2019s thyroiditis: A nationwide cohort study","volume":"109","author":"Chen","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1667\/RR2240.1","article-title":"Risk of Second Primary Thyroid Cancer after Radiotherapy for a Childhood Cancer in a Large Cohort Study: An Update from the Childhood Cancer Survivor Study","volume":"174","author":"Bhatti","year":"2010","journal-title":"Radiat. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Trinh, L., Crawford, A., Hussein, M., Zerfaoui, M., Toraih, E., Randolph, G., and Kandil, E. (2021). Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy\u2014Who Is at the Greatest Risk?. Cancers, 13.","DOI":"10.3390\/cancers13061402"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/MNM.0000000000000419","article-title":"Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: A systematic review and meta-analysis","volume":"37","author":"Zhang","year":"2016","journal-title":"Nucl. Med. Commun."},{"key":"ref_9","first-page":"2431","article-title":"Radiation-induced second malignancies","volume":"35","author":"Mahmood","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/sj.bjc.6605624","article-title":"Cancer risk in patients hospitalised for Graves\u2019 disease: A population-based cohort study in Sweden","volume":"102","author":"Shu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.21037\/gs-20-878","article-title":"Thyroid disease is associated with an increased risk of breast cancer: A systematic review and meta-analysis","volume":"10","author":"Chen","year":"2021","journal-title":"Gland Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12282-020-01078-z","article-title":"Breast cancer populations may have an increased prevalence of thyroglobulin antibody and thyroid peroxidase antibody: A systematic review and meta-analysis","volume":"27","author":"Pan","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_13","first-page":"1317","article-title":"High prevalence of hypothyroidism among patients with cutaneous melanoma","volume":"10","author":"Ellerhorst","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D33RN7K0D8","article-title":"High prevalence of hypothyroidism in male patients with cutaneous melanoma","volume":"12","author":"Shah","year":"2006","journal-title":"Dermatol. Online J."},{"key":"ref_15","first-page":"39","article-title":"Melanoma and Thyroid Carcinoma: Our Current Understanding","volume":"12","author":"Lazzara","year":"2019","journal-title":"J. Clin. Aesthetic Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/bmb\/ldr030","article-title":"The epidemiology of thyroid disease","volume":"99","author":"Vanderpump","year":"2011","journal-title":"Br. Med Bull."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00423-011-0788-5","article-title":"Molecular pathogenesis of nodular goiter","volume":"396","author":"Paschke","year":"2011","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijsu.2017.03.020","article-title":"New perspectives in the diagnosis of thyroid follicular lesions","volume":"41","author":"Baldini","year":"2017","journal-title":"Int. J. Surg."},{"key":"ref_20","unstructured":"Nikiforov, Y.E., Biddinger, P.W., and Thompson, L.D.R. (2009). Diagnostic Pathology and Molecular Genetics of the Thyroid, Wolters Kluwer\u2014Lippincott Williams & Wilkins."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.21037\/gs.2017.11.07","article-title":"Molecular testing in the diagnosis of differentiated thyroid carcinomas","volume":"7","author":"Ferrari","year":"2018","journal-title":"Gland Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1089\/thy.2006.16.1151","article-title":"Trend in Thyroid Carcinoma Size, Age at Diagnosis, and Histology in a Retrospective Study of 500 Cases Diagnosed Over 20 Years","volume":"16","author":"Trimboli","year":"2006","journal-title":"Thyroid"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2265.2007.03158.x","article-title":"Analysis of clinical, ultrasound and colour flow-Doppler characteristics in predicting malignancy in follicular thyroid neoplasms","volume":"69","author":"Trimboli","year":"2008","journal-title":"Clin. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/jcp.24242","article-title":"Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: Validation of molecular markers and technology innovation","volume":"228","author":"Papale","year":"2013","journal-title":"J. Cell. Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/thy.2008.0338","article-title":"Comparison of Malignancy Rate in Thyroid Nodules with Cytology of Indeterminate Follicular or Indeterminate H\u00fcrthle Cell Neoplasm","volume":"19","author":"Sorrenti","year":"2009","journal-title":"Thyroid"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9692304","DOI":"10.1155\/2017\/9692304","article-title":"Thyroid Imaging Reporting and Data System Score Combined with the New Italian Classification for Thyroid Cytology Improves the Clinical Management of Indeterminate Nodules","volume":"2017","author":"Ulisse","year":"2017","journal-title":"Int. J. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.21037\/gs-2019-catp-26","article-title":"Molecular testing and thyroid nodule management in North America","volume":"9","author":"Ohori","year":"2020","journal-title":"Gland Surg."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fresilli, D., David, E., Pacini, P., Del Gaudio, G., Dolcetti, V., Lucarelli, G., Di Leo, N., Bellini, M., D\u2019Andrea, V., and Sorrenti, S. (2021). Thyroid Nodule Characterization: How to Assess the Malignancy Risk. Update of the Literature. Diagnostics, 11.","DOI":"10.3390\/diagnostics11081374"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sorrenti, S., Dolcetti, V., Fresilli, D., Del Gaudio, G., Pacini, P., Huang, P., Camponovo, C., Leoncini, A., D\u2019Andrea, V., and Pironi, D. (2021). The Role of CEUS in the Evaluation of Thyroid Cancer: From Diagnosis to Local Staging. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194559"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3389\/fendo.2020.00551","article-title":"Predictive Factors of Lymph Node Metastasis in Patients with Papillary Microcarcinoma of the Thyroid: Retrospective Analysis on 293 Cases","volume":"11","author":"Medas","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/thy.2018.0736","article-title":"Identification of Rare Variants Predisposing to Thyroid Cancer","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"R577","DOI":"10.1530\/ERC-16-0067","article-title":"Familial non-medullary thyroid cancer: Unraveling the genetic maze","volume":"23","author":"Yang","year":"2016","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/thy.2010.0256","article-title":"Prevalence, Clinicopathologic Features, and Somatic Genetic Mutation Profile in Familial Versus Sporadic Nonmedullary Thyroid Cancer","volume":"21","author":"Moses","year":"2011","journal-title":"Thyroid"},{"key":"ref_34","unstructured":"Cancer Genome Atlas Research Network (2014). Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 159, 676\u2013690."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yoo, S.-K., Lee, S., Kim, S.-J., Jee, H.-G., Kim, B.-A., Cho, H., Song, Y.S., Cho, S.W., Won, J.-K., and Shin, J.-Y. (2016). Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006239"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2174\/138920211798120853","article-title":"Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas","volume":"12","author":"Soares","year":"2011","journal-title":"Curr. Genom."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Baldini, E., Tuccilli, C., Pironi, D., Catania, A., Tartaglia, F., Di Matteo, F.M., Palumbo, P., Arcieri, S., Mascagni, D., and Palazzini, G. (2021). Expression and Clinical Utility of Transcription Factors Involved in Epithelial\u2013Mesenchymal Transition during Thyroid Cancer Progression. J. Clin. Med., 10.","DOI":"10.3390\/jcm10184076"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ulisse, S., Baldini, E., Lauro, A., Pironi, D., Tripodi, D., Lori, E., Ferent, I.C., Amabile, M.I., Catania, A., and Di Matteo, F.M. (2021). Papillary Thyroid Cancer Prognosis: An Evolving Field. Cancers, 13.","DOI":"10.3390\/cancers13215567"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sorrenti, S., Carbotta, G., Di Matteo, F.M., Catania, A., Pironi, D., Tartaglia, F., Tarroni, D., Gagliardi, F., Tripodi, D., and Watanabe, M. (2020). Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study. Cancers, 12.","DOI":"10.3390\/cancers12123637"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/jc.2010-1688","article-title":"High Expression of the Urokinase Plasminogen Activator and Its Cognate Receptor Associates with Advanced Stages and Reduced Disease-Free Interval in Papillary Thyroid Carcinoma","volume":"96","author":"Ulisse","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2265.2012.04465.x","article-title":"In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval","volume":"77","author":"Ulisse","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Baldini, E., Tuccilli, C., Prinzi, N., Sorrenti, S., Falvo, L., DE Vito, C., Catania, A., Tartaglia, F., Mocini, R., and Coccaro, C. (2015). Deregulated Expression of Aurora Kinases Is Not a Prognostic Biomarker in Papillary Thyroid Cancer Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121514"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40463-018-0254-2","article-title":"Does hyperthyroidism worsen prognosis of thyroid carcinoma? A retrospective analysis on 2820 consecutive thyroidectomies","volume":"47","author":"Medas","year":"2018","journal-title":"J. Otolaryngol.-Head Neck Surg."},{"key":"ref_44","first-page":"2225","article-title":"Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_45","first-page":"2306","article-title":"Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo","volume":"39","author":"Ferrari","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"901004","DOI":"10.3389\/fonc.2022.901004","article-title":"Predictive Biomarkers in Thyroid Cancer","volume":"12","author":"Macerola","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1530\/ERC-14-0299","article-title":"Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines","volume":"21","author":"Baldini","year":"2014","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ragusa, F., Ferrari, S.M., Elia, G., Paparo, S.R., Balestri, E., Botrini, C., Patrizio, A., Mazzi, V., Guglielmi, G., and Foddis, R. (2022). Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105731"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ulisse, S., Tuccilli, C., Sorrenti, S., Antonelli, A., Fallahi, P., D\u2019Armiento, E., Catania, A., Tartaglia, F., Amabile, M.I., and Giacomelli, L. (2019). PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061405"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"174295","DOI":"10.1155\/2018\/1742951","article-title":"CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers","volume":"2018","author":"Tuccilli","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Baldini, E., Presutti, D., Favoriti, P., Santini, S., Papoff, G., Tuccilli, C., Carletti, R., Di Gioia, C., Lori, E., and Ferent, I.C. (2022). In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073724"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40259-013-0049-y","article-title":"Sorafenib and Thyroid Cancer","volume":"27","author":"Fallahi","year":"2013","journal-title":"BioDrugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2014.02.003","article-title":"Melanosome transfer: It is best to give and receive","volume":"29","author":"Wu","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11912-018-0732-8","article-title":"The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe","volume":"20","author":"Dimitriou","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1038\/s41467-022-31510-1","article-title":"Multi-modal molecular programs regulate melanoma cell state","volume":"13","author":"Andrews","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103425","DOI":"10.1016\/j.critrevonc.2021.103425","article-title":"Molecular landscape of Hereditary Melanoma","volume":"164","author":"Arnaut","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_59","unstructured":"Elder, D.E., Massi, D., Scolyer, R.A., and Willemze, R. (2018). Melanocytic tumour classification and the pathway concept of melanoma pathogenesis. WHO Classification of Skin Tumours, International Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjd.20427","article-title":"Melanoma pathology: New approaches and classification*","volume":"185","author":"Yeh","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"675296","DOI":"10.3389\/fonc.2021.675296","article-title":"The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions from Routine Practice","volume":"11","author":"Ferrara","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2019.11.014","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics\u2014Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final Version of 2009 AJCC Melanoma Staging and Classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1600-0560.2012.01955.x","article-title":"Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity","volume":"39","author":"Cianfarani","year":"2012","journal-title":"J. Cutan. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): Distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1097\/00008390-200112000-00010","article-title":"Autoimmunity and hypothyroidism in patients with uveal melanoma","volume":"11","author":"Ellerhorst","year":"2001","journal-title":"Melanoma Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ferrari, S.M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M.R., Baldini, E., Ulisse, S., and Marone, G. (2019). Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102560"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41571-020-0397-8","article-title":"ICI for resected stage IV melanoma","volume":"17","author":"Killock","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","article-title":"Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting","volume":"32","author":"Herrscher","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Dawidowska, A., Jagodzinska-Mucha, P., Kose\u0142a-Paterczyk, H., Jaczewska, S., Sobczuk, P., Chelstowska, M., Kowalska, M., Badziak-Sterczewska, H., Poleszczuk, J., and Rutkowski, P. (2022). Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma. Cancers, 14.","DOI":"10.3390\/cancers14051248"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., and Schaeverbeke, T. (2015). Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis. BMC Med., 13.","DOI":"10.1186\/s12916-015-0455-8"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential Immune-Related Adverse Events Associated with Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti\u2013PD-1 antibodies in cancer patients","volume":"109","author":"Rogado","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-016-3073-z","article-title":"Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials","volume":"78","author":"Bilen","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/jamaoto.2014.78","article-title":"Increased Melanoma Risk in Individuals with Papillary Thyroid Carcinoma","volume":"140","author":"Oakley","year":"2014","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kim, Y.J., Lee, M., Kim, E.H., Jung, I., and Lee, C.S. (2021). Coexisting and Second Primary Cancers in Patients with Uveal Melanoma: A 10-Year Nationwide Database Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10204744"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.canep.2019.101664","article-title":"Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000\u20132015","volume":"64","author":"Schonfeld","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"370","DOI":"10.5021\/ad.2010.22.3.370","article-title":"Cutaneous Malignant Melanoma Associated with Papillary Thyroid Cancer","volume":"22","author":"Kim","year":"2010","journal-title":"Ann. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13256-022-03258-1","article-title":"Concomitant uveal melanoma and papillary thyroid carcinoma: A case report","volume":"16","author":"Kolaii","year":"2022","journal-title":"J. Med Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Zerfaoui, M., Dokunmu, T., Toraih, E., Rezk, B., Elmageed, Z.A., and Kandil, E. (2021). New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking. Cells, 10.","DOI":"10.3390\/cells10020367"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ced.14153","article-title":"Malignant melanoma, papillary thyroid carcinoma and Erdheim\u2013Chester disease, associated with both BRAF V600E and mosaic Turner syndrome","volume":"45","author":"Papanikolaou","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1530\/EJE-15-0605","article-title":"ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome","volume":"174","author":"Tavares","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-016-0879-9","article-title":"KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma","volume":"34","author":"Cicenas","year":"2017","journal-title":"Med Oncol."},{"key":"ref_93","unstructured":"Greenspan, F.S., and Gardner, D.G. (2004). The thyroid gland. Basic & Clinical Endocrinology, Lange Medical Books\/McGraw-Hill. [7th ed.]."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime Cancer Risks in Individuals with Germline PTEN Mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ng.2947","article-title":"POT1 loss-of-function variants predispose to familial melanoma","volume":"46","author":"Harland","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjd.17443","article-title":"POT 1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families","volume":"181","author":"Potrony","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1001\/jamadermatol.2018.3662","article-title":"Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma","volume":"155","author":"Wong","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Srivastava, A., Miao, B., Skopelitou, D., Kumar, V., Kumar, A., Paramasivam, N., Bonora, E., Hemminki, K., F\u00f6rsti, A., and Bandapalli, O.R. (2020). A Germline Mutation in the POT1 Gene Is a Candidate for Familial Non-Medullary Thyroid Cancer. Cancers, 12.","DOI":"10.1101\/2020.03.23.004663"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12672-020-00383-5","article-title":"Lack of Mutations in POT1 Gene in Selected Families with Familial Non-Medullary Thyroid Cancer","volume":"11","author":"Orois","year":"2020","journal-title":"Horm. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cancergen.2015.12.007","article-title":"A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer","volume":"209","author":"McDonnell","year":"2015","journal-title":"Cancer Genet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jcem-59-3-432","article-title":"Identification of Immunoreactive Thyrotropin-Releasing Hormone in Human Neoplasia","volume":"59","author":"Wilber","year":"1984","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1046\/j.1523-1747.2002.19617.x","article-title":"Expression of Hypothalamic\u2013Pituitary\u2013Thyroid Axis RelatedGenes in the Human Skin","volume":"119","author":"Slominski","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1158\/1078-0432.CCR-03-0368","article-title":"Expression of Thyrotropin-Releasing Hormone by Human Melanoma and Nevi","volume":"10","author":"Ellerhorst","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0196-9781(98)00168-5","article-title":"Thyrotropin releasing hormone (TRH) selectively binds and activates the melanocortin 1 receptor","volume":"20","author":"Prusis","year":"1999","journal-title":"Peptides"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/jid.2011.221","article-title":"Thyrotropin-Releasing Hormone Selectively Stimulates Human Hair Follicle Pigmentation","volume":"131","author":"Hardenbicker","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Chu, Y.-D., and Yeh, C.-T. (2020). The Molecular Function and Clinical Role of Thyroid Stimulating Hormone Receptor in Cancer Cells. Cells, 9.","DOI":"10.3390\/cells9071730"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/jid.2009.180","article-title":"TSH Receptor and Thyroid-Specific Gene Expression in Human Skin","volume":"130","author":"Cianfarani","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/jid.2008.361","article-title":"Human Female Hair Follicles Are a Direct, Nonclassical Target for Thyroid-Stimulating Hormone","volume":"129","author":"Kromminga","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1677\/erc.1.01239","article-title":"Human melanoma cells express functional receptors for thyroid-stimulating hormone","volume":"13","author":"Ellerhorst","year":"2006","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000339817","article-title":"Functional TSH Receptors, Malignant Melanomas and Subclinical Hypothyroidism","volume":"1","author":"Ursu","year":"2012","journal-title":"Eur. Thyroid J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/er.2009-0007","article-title":"Molecular Aspects of Thyroid Hormone Actions","volume":"31","author":"Cheng","year":"2010","journal-title":"Endocr. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrendo.2015.205","article-title":"Nongenomic actions of thyroid hormone","volume":"12","author":"Davis","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000343695","article-title":"Thyroid Hormone Transporters and Resistance","volume":"24","author":"Visser","year":"2013","journal-title":"Endocr. Dev."},{"key":"ref_114","unstructured":"Parker, M.G. (1991). Nuclear thyroid hormone receptors. Nuclear Hormone Receptor, Academic Press."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Sidhaye","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1172\/JCI114906","article-title":"Nuclear thyroid hormone receptors","volume":"86","author":"Lazar","year":"1990","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/324635a0","article-title":"The c-erb-A protein is a high-affinity receptor for thyroid hormone","volume":"324","author":"Sap","year":"1986","journal-title":"Nature"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/324641a0","article-title":"The c-erb-A gene encodes a thyroid hormone receptor","volume":"324","author":"Weinberger","year":"1986","journal-title":"Nature"},{"key":"ref_119","first-page":"1278","article-title":"Identification of Transcripts Initiated from an Internal Promoter in the c-erbA\u03b1 Locus That Encode Inhibitors of Retinoic Acid Receptor-\u03b1 and Triiodothyronine Receptor Activities","volume":"11","author":"Chassande","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/emboj\/18.3.623","article-title":"Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development","volume":"18","author":"Gauthier","year":"1999","journal-title":"EMBO J."},{"key":"ref_121","first-page":"1221","article-title":"Thyroid Hormone, Cancer, and Apoptosis","volume":"6","author":"Lin","year":"2011","journal-title":"Compr. Physiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"C980","DOI":"10.1152\/ajpcell.00305.2008","article-title":"l-Thyroxine vs. 3,5,3\u2032-triiodo-l-thyronine and cell proliferation: Activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase","volume":"296","author":"Lin","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.1256251","article-title":"Thyroid hormone\u2013dependent adult pigment cell lineage and pattern in zebrafish","volume":"345","author":"McMenamin","year":"2014","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Guillot, R., Muriach, B., Rocha, A., Rotllant, J., Kelsh, R., and Cerd\u00e1-Reverter, J.M. (2016). Thyroid Hormones Regulate Zebrafish Melanogenesis in a Gender-Specific Manner. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166152"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1089\/thy.2020.0391","article-title":"Germ Line Mutations in the Thyroid Hormone Receptor Alpha Gene Predispose to Cutaneous Tags and Melanocytic Nevi","volume":"31","author":"Moran","year":"2021","journal-title":"Thyroid"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.canep.2020.101707","article-title":"Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers\u2014A cohort study of the Swedish population","volume":"66","author":"Carlsson","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"djv221","DOI":"10.1093\/jnci\/djv221","article-title":"Gender Disparity and Mutation Burden in Metastatic Melanoma","volume":"107","author":"Gupta","year":"2015","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_128","first-page":"302","article-title":"Is oestrogen an important player in melanoma progression?","volume":"18","author":"Janick","year":"2014","journal-title":"Contemp. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12967-022-03358-y","article-title":"Targeting ER\u03b2 to fight melanoma: A new valid approach?","volume":"20","author":"Migliaccio","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.jid.2021.12.028","article-title":"Therapeutic Potential of Nitric Oxide\u2014Releasing Selective Estrogen Receptor Modulators in Malignant Melanoma","volume":"142","author":"Bechmann","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2012.44.5031","article-title":"Sex Is an Independent Prognostic Indicator for Survival and Relapse\/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials","volume":"31","author":"Joosse","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40487-020-00109-1","article-title":"Gender Differences and Outcomes in Melanoma Patients","volume":"8","author":"Morgese","year":"2020","journal-title":"Oncol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/jid.2010.354","article-title":"Gender Differences in Melanoma Survival: Female Patients Have a Decreased Risk of Metastasis","volume":"131","author":"Joosse","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/CMR.0b013e32834577c8","article-title":"Sex differences in survival of cutaneous melanoma are age dependent: An analysis of 7338 patients","volume":"21","author":"Mervic","year":"2011","journal-title":"Melanoma Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1677\/JOE-09-0242","article-title":"The unfolding stories of GPR30, a new membrane-bound estrogen receptor","volume":"204","author":"Maggiolini","year":"2010","journal-title":"J. Endocrinol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.tips.2016.10.006","article-title":"Estrogen Receptor \u03b2 as a Pharmaceutical Target","volume":"38","author":"Warner","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0303-7207(94)90034-5","article-title":"Thyroid hormone and glucocorticoid independently regulate the expression of estrogen receptor in male Xenopus liver cells","volume":"105","author":"Ulisse","year":"1994","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1210\/en.2002-0092","article-title":"Thyroid Hormone Is an Inhibitor of Estrogen-Induced Degradation of Estrogen Receptor-\u03b1 Protein: Estrogen-Dependent Proteolysis Is Not Essential for Receptor Transactivation Function in the Pituitary","volume":"144","author":"Alarid","year":"2003","journal-title":"Endocrinology"},{"key":"ref_140","first-page":"157","article-title":"Regulation of gene expression by the thyroid hormone receptor","volume":"1032","author":"Glass","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1210\/en.2004-0308","article-title":"Thyroid Hormone Causes Mitogen-Activated Protein Kinase-Dependent Phosphorylation of the Nuclear Estrogen Receptor","volume":"145","author":"Tang","year":"2004","journal-title":"Endocrinology"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12672-018-0326-9","article-title":"Thyroid Hormone in the Clinic and Breast Cancer","volume":"9","author":"Hercbergs","year":"2018","journal-title":"Horm. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.beem.2015.04.001","article-title":"Overlapping nongenomic and genomic actions of thyroid hormone and steroids","volume":"29","author":"Hammes","year":"2015","journal-title":"Best Pr. Res. Clin. Endocrinol. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:22:27Z","timestamp":1760142147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/10036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":143,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231710036"],"URL":"https:\/\/doi.org\/10.3390\/ijms231710036","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}